Lara Fallon

3.3k total citations · 2 hit papers
62 papers, 2.4k citations indexed

About

Lara Fallon is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Lara Fallon has authored 62 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Rheumatology, 25 papers in Hematology and 22 papers in Immunology. Recurrent topics in Lara Fallon's work include Spondyloarthritis Studies and Treatments (33 papers), Rheumatoid Arthritis Research and Therapies (33 papers) and Autoimmune and Inflammatory Disorders Research (25 papers). Lara Fallon is often cited by papers focused on Spondyloarthritis Studies and Treatments (33 papers), Rheumatoid Arthritis Research and Therapies (33 papers) and Autoimmune and Inflammatory Disorders Research (25 papers). Lara Fallon collaborates with scholars based in United States, Canada and United Kingdom. Lara Fallon's co-authors include Zhihua Liu, Peter T. Lansbury, Yichin Liu, Hilal A. Lashuel, Edward A. Fon, Michael C. Pirrung, France Moreau, Maria Kontogiannea, Cunshan Wang and Elsa Regan‐Klapisz and has published in prestigious journals such as Cell, The Lancet and Journal of the American Chemical Society.

In The Last Decade

Lara Fallon

60 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect α-Synuclein Degradation and Parkinson's Disease Susceptibility

2002 652 citations Lara Fallon et al. profile →
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

2021 159 citations Atul Deodhar, Huji Xu et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lara Fallon United States	21	1.0k	625	504	403	391	62	2.4k
Tracy Stites United States	14	1.5k 1.5×	473 0.8×	833 1.7×	61 0.2×	502 1.3×	21	3.4k
Fulvio Baggi Italy	30	597 0.6×	127 0.2×	1.4k 2.7×	107 0.3×	408 1.0×	86	2.6k
Irene Slavc Austria	32	1.3k 1.3×	79 0.1×	876 1.7×	161 0.4×	112 0.3×	131	3.2k
Baodong Sun United States	32	893 0.9×	577 0.9×	174 0.3×	279 0.7×	65 0.2×	84	2.5k
Giancarlo Castellano Spain	30	1.3k 1.3×	89 0.1×	270 0.5×	160 0.4×	299 0.8×	98	2.9k
Amanda Littlewood‐Evans Switzerland	24	1.4k 1.4×	198 0.3×	54 0.1×	121 0.3×	583 1.5×	30	2.4k
Xiaoping Jiang China	25	640 0.6×	121 0.2×	86 0.2×	283 0.7×	204 0.5×	54	2.2k
Elena Di Gennaro Italy	34	1.5k 1.5×	190 0.3×	126 0.3×	188 0.5×	111 0.3×	99	2.7k
Reiko Kato Japan	24	1.8k 1.8×	89 0.1×	204 0.4×	112 0.3×	406 1.0×	54	2.6k
Annet Hammacher Australia	26	1.6k 1.6×	128 0.2×	86 0.2×	174 0.4×	738 1.9×	43	3.4k

Countries citing papers authored by Lara Fallon

Since Specialization

Citations

This map shows the geographic impact of Lara Fallon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lara Fallon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lara Fallon more than expected).

Fields of papers citing papers by Lara Fallon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lara Fallon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lara Fallon. The network helps show where Lara Fallon may publish in the future.

Co-authorship network of co-authors of Lara Fallon

This figure shows the co-authorship network connecting the top 25 collaborators of Lara Fallon. A scholar is included among the top collaborators of Lara Fallon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lara Fallon. Lara Fallon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Mease, Philip J., Lara Fallon, Rajiv Mundayat, et al.. (2024). Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatology and Therapy. 11(2). 313–329. 3 indexed citations

2.

Menon, Sujatha, et al.. (2024). Exposure–Response Analysis of Tofacitinib in Active Psoriatic Arthritis: Results from Two Phase 3 Studies. The Journal of Clinical Pharmacology. 65(3). 369–377. 1 indexed citations

3.

Deodhar, Atul, Servet Akar, Jeffrey R. Curtis, et al.. (2024). Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis. Advances in Rheumatology. 64(1). 87–87. 1 indexed citations

4.

Kristensen, Lars Erik, Atul Deodhar, Ying Ying Leung, et al.. (2024). Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data. Rheumatology and Therapy. 11(3). 487–499. 3 indexed citations

5.

Østergaard, Mikkel, Joseph Wu, Lara Fallon, et al.. (2023). Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial. Rheumatology and Therapy. 10(4). 1001–1020. 2 indexed citations

6.

Burmester, Gerd R, Laura C. Coates, Stanley Cohen, et al.. (2023). Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis. Rheumatology and Therapy. 10(5). 1255–1276. 6 indexed citations

7.

Deodhar, Atul, Helena Marzo‐Ortega, Joseph Wu, et al.. (2023). Tofacitinib Efficacy and Safety in Patients With Ankylosing Spondylitis by Prior Biologic Disease‐Modifying Antirheumatic Drug Use: A Post Hoc Analysis. ACR Open Rheumatology. 5(12). 632–643. 4 indexed citations

8.

Parnell, Andrew, Vimal Chandran, Lara Fallon, et al.. (2022). POS1045 MASS SPECTROMETRY-BASED PROTEOMICS FOR THE IDENTIFICATION OF CANDIDATE SERUM PROTEIN BIOMARKERS THAT MAY PREDICT TREATMENT RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS. Annals of the Rheumatic Diseases. 81. 840–841. 1 indexed citations

9.

Gladman, Dafna D., Laura C. Coates, Joseph Wu, et al.. (2022). Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo. Arthritis Research & Therapy. 24(1). 40–40. 5 indexed citations

10.

Nash, Peter, Laura C. Coates, Dona Fleishaker, et al.. (2021). Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. The Lancet.

11.

Deodhar, Atul, Huji Xu, Xenofon Baraliakos, et al.. (2021). Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Annals of the Rheumatic Diseases. 80(8). 1004–1013. 159 indexed citations breakdown →

12.

Nash, Peter, Laura C. Coates, Dona Fleishaker, et al.. (2021). Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. The Lancet Rheumatology. 3(4). e270–e283. 27 indexed citations

13.

Coates, Laura C., Ana‐Maria Orbai, Valderílio Feijó Azevedo, et al.. (2020). Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire. Health and Quality of Life Outcomes. 18(1). 173–173. 39 indexed citations

14.

Nash, Peter, Philip J. Mease, Dona Fleishaker, et al.. (2020). Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance. The Lancet Rheumatology. 3(1). e28–e39. 15 indexed citations

15.

Taylor, Peter C., Neil Betteridge, T. Michelle Brown, et al.. (2020). <p>Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making</p>. Patient Preference and Adherence. Volume 14. 119–131. 15 indexed citations

16.

Nash, Peter, Laura C. Coates, Alan Kivitz, et al.. (2020). Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study. Rheumatology and Therapy. 7(3). 553–580. 48 indexed citations

17.

Heijde, Désirée van der, Dafna D. Gladman, Oliver FitzGerald, et al.. (2019). Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. The Journal of Rheumatology. 46(9). 1089–1096. 39 indexed citations

18.

Gottlieb, Alice B., Jordi Gratacós, Ara Dikranian, et al.. (2018). Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe. Rheumatology International. 39(1). 121–130. 20 indexed citations

19.

Heijde, D. van der, Dafna D. Gladman, Oliver FitzGerald, et al.. (2017). Tofacitinib Treatment in Patients with Psoriatic Arthritis and Rates of Radiologic Progression According to Baseline CRP Levels : Results from a Phase 3 Clinical Study. Arthritis & Rheumatism. 69. 1 indexed citations

20.

Irish, William, Philip A. Saynisch, Peter J. Mallow, Lara Fallon, & Candace Gunnarsson. (2015). Using the medicare claims database to understand the Economic burden of Liver disease: a case study in Hepatic Encephalopathy. Value in Health. 18(3). A226–A226. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact